Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD.

Elife. 2019 Sep 3;8. pii: e47327. doi: 10.7554/eLife.47327.

2.

Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.

Kleinschmidt EG, Miller NLG, Ozmadenci D, Tancioni I, Osterman CD, Barrie AM, Taylor KN, Ye A, Jiang S, Connolly DC, Stupack DG, Schlaepfer DD.

Oncogene. 2019 Sep;38(36):6323-6337. doi: 10.1038/s41388-019-0881-8. Epub 2019 Jul 15.

PMID:
31308489
3.

CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.

Gao R, Li D, Xun J, Zhou W, Li J, Wang J, Liu C, Li X, Shen W, Qiao H, Stupack DG, Luo N.

Theranostics. 2018 Nov 29;8(22):6248-6262. doi: 10.7150/thno.28721. eCollection 2018.

4.

PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.

Gao R, Liu Y, Li D, Xun J, Zhou W, Wang P, Liu C, Li X, Shen W, Su W, Qiao H, Stupack DG, Luo N.

Cell Physiol Biochem. 2018;50(6):2108-2123. doi: 10.1159/000495055. Epub 2018 Nov 9.

5.

Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer.

Delaney JR, Patel CB, Willis KM, Haghighiabyaneh M, Axelrod J, Tancioni I, Lu D, Bapat J, Young S, Cadassou O, Bartakova A, Sheth P, Haft C, Hui S, Saenz C, Schlaepfer DD, Harismendy O, Stupack DG.

Nat Commun. 2017 Feb 15;8:14423. doi: 10.1038/ncomms14423.

6.

Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations.

Burgoyne AM, De Siena M, Alkhuziem M, Tang CM, Medina B, Fanta PT, Belinsky MG, von Mehren M, Thorson JA, Madlensky L, Bowler T, D'Angelo F, Stupack DG, Harismendy O, DeMatteo RP, Sicklick JK.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00014. Epub 2017 Aug 15.

7.
8.

Nelfinavir is effective against human cervical cancer cells in vivo: a potential treatment modality in resource-limited settings.

Davis MA, Delaney JR, Patel CB, Storgard R, Stupack DG.

Drug Des Devel Ther. 2016 Jun 2;10:1837-46. doi: 10.2147/DDDT.S102241. eCollection 2016.

9.

JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms.

Zhang Y, Shen L, Stupack DG, Bai N, Xun J, Ren G, Han J, Li L, Luo Y, Xiang R, Tan X.

Oncotarget. 2016 May 17;7(20):29387-99. doi: 10.18632/oncotarget.8836.

10.

TIFA, an inflammatory signaling adaptor, is tumor suppressive for liver cancer.

Shen W, Chang A, Wang J, Zhou W, Gao R, Li J, Xu Y, Luo X, Xiang R, Luo N, Stupack DG.

Oncogenesis. 2015 Oct 26;4:e173. doi: 10.1038/oncsis.2015.30.

11.

A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer.

Delaney JR, Patel C, McCabe KE, Lu D, Davis MA, Tancioni I, von Schalscha T, Bartakova A, Haft C, Schlaepfer DD, Stupack DG.

Oncotarget. 2015 Oct 13;6(31):31104-18. doi: 10.18632/oncotarget.5093.

12.

Role of Hyaluronan and Glucose on 4-Methylumbelliferone-inhibited Cell Proliferation in Breast Carcinoma Cells.

Wang R, Zhou W, Wang J, Liu Y, Chen Y, Jiang S, Luo X, Stupack DG, Luo N.

Anticancer Res. 2015 Sep;35(9):4799-805.

PMID:
26254370
13.

Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.

Young SA, McCabe KE, Bartakova A, Delaney J, Pizzo DP, Newbury RO, Varner JA, Schlaepfer DD, Stupack DG.

PLoS One. 2015 May 14;10(5):e0120815. doi: 10.1371/journal.pone.0120815. eCollection 2015.

14.

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.

McCabe KE, Bacos K, Lu D, Delaney JR, Axelrod J, Potter MD, Vamos M, Wong V, Cosford ND, Xiang R, Stupack DG.

Cell Death Dis. 2014 Oct 30;5:e1496. doi: 10.1038/cddis.2014.448.

15.

The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth.

Sayyah J, Bartakova A, Nogal N, Quilliam LA, Stupack DG, Brown JH.

J Biol Chem. 2014 Jun 20;289(25):17689-98. doi: 10.1074/jbc.M113.536227. Epub 2014 May 1.

16.

Tumor angiogenesis: putting a value on plastic GEMMs.

Cheresh DA, Stupack DG.

Circ Res. 2014 Jan 3;114(1):9-11. doi: 10.1161/CIRCRESAHA.113.302812. No abstract available.

17.

Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, Uryu S, Kim J, Tarin D, Stupack DG, Plaxe SC, Schlaepfer DD.

Clin Exp Metastasis. 2013 Jun;30(5):579-94. doi: 10.1007/s10585-012-9562-5. Epub 2012 Dec 30.

18.

EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.

Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh DA.

PLoS One. 2012;7(5):e36753. doi: 10.1371/journal.pone.0036753. Epub 2012 May 7.

19.

Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy.

Lu D, Chen S, Tan X, Li N, Liu C, Li Z, Liu Z, Stupack DG, Reisfeld RA, Xiang R.

Cancer Res. 2012 Jul 15;72(14):3451-6. doi: 10.1158/0008-5472.CAN-11-2536. Epub 2012 May 14.

20.

Caspase-8 isoform 6 promotes death effector filament formation independent of microtubules.

Yuan RT, Young S, Liang J, Schmid MC, Mielgo A, Stupack DG.

Apoptosis. 2012 Mar;17(3):229-35. doi: 10.1007/s10495-011-0677-y.

PMID:
22160860
21.

EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation.

Huang M, Anand S, Murphy EA, Desgrosellier JS, Stupack DG, Shattil SJ, Schlaepfer DD, Cheresh DA.

Oncogene. 2012 May 31;31(22):2783-93. doi: 10.1038/onc.2011.450. Epub 2011 Oct 3.

22.

Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts.

DE Wever O, Sobczak-Thépot J, Vercoutter-Edouart AS, Michalski JC, Ouelaa-Benslama R, Stupack DG, Bracke M, Wang JYJ, Gespach C, Emami S.

Int J Oncol. 2011 Aug;39(2):393-400. doi: 10.3892/ijo.2011.1034. Epub 2011 May 9.

23.

Rab5 in the regulation of cell motility and invasion.

Torres VA, Stupack DG.

Curr Protein Pept Sci. 2011 Feb;12(1):43-51. Review.

PMID:
21190523
24.

Caspase-8 as a therapeutic target in cancer.

Stupack DG.

Cancer Lett. 2013 May 28;332(2):133-40. doi: 10.1016/j.canlet.2010.07.022. Epub 2010 Sep 3. Review.

25.

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, Phillips A, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD.

Cancer Biol Ther. 2010 May 15;9(10):778-90.

26.

PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.

Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Lim ST, Liang C, Koenig M, Sun C, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD.

Cancer Biol Ther. 2010 May 15;9(10):764-77.

27.

The death effector domains of caspase-8 induce terminal differentiation.

Mielgo A, Torres VA, Schmid MC, Graf R, Zeitlin SG, Lee P, Shields DJ, Barbero S, Jamora C, Stupack DG.

PLoS One. 2009 Nov 18;4(11):e7879. doi: 10.1371/journal.pone.0007879.

28.

Rab5 mediates caspase-8-promoted cell motility and metastasis.

Torres VA, Mielgo A, Barbero S, Hsiao R, Wilkins JA, Stupack DG.

Mol Biol Cell. 2010 Jan 15;21(2):369-76. doi: 10.1091/mbc.E09-09-0769. Epub 2009 Nov 18.

29.

Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules.

Mielgo A, Torres VA, Clair K, Barbero S, Stupack DG.

Oncogene. 2009 Oct 8;28(40):3551-62. doi: 10.1038/onc.2009.210. Epub 2009 Aug 10.

30.

Agonizing integrin antagonists?

Weis SM, Stupack DG, Cheresh DA.

Cancer Cell. 2009 May 5;15(5):359-61. doi: 10.1016/j.ccr.2009.04.005.

31.

Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis.

Barbero S, Mielgo A, Torres V, Teitz T, Shields DJ, Mikolon D, Bogyo M, Barilà D, Lahti JM, Schlaepfer D, Stupack DG.

Cancer Res. 2009 May 1;69(9):3755-63. doi: 10.1158/0008-5472.CAN-08-3937. Epub 2009 Apr 21.

32.

Regulation of angiogenesis: apoptotic cues from the ECM.

Cheresh DA, Stupack DG.

Oncogene. 2008 Oct 20;27(48):6285-98. doi: 10.1038/onc.2008.304. Review.

PMID:
18931694
33.

FERM control of FAK function: implications for cancer therapy.

Lim ST, Mikolon D, Stupack DG, Schlaepfer DD.

Cell Cycle. 2008 Aug;7(15):2306-14. Epub 2008 May 29. Review.

34.

The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8.

Wrasidlo W, Mielgo A, Torres VA, Barbero S, Stoletov K, Suyama TL, Klemke RL, Gerwick WH, Carson DA, Stupack DG.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2313-8. doi: 10.1073/pnas.0712198105. Epub 2008 Feb 11.

35.

The biology of integrins.

Stupack DG.

Oncology (Williston Park). 2007 Aug;21(9 Suppl 3):6-12. Review.

36.

Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility.

Wu L, Bernard-Trifilo JA, Lim Y, Lim ST, Mitra SK, Uryu S, Chen M, Pallen CJ, Cheung NK, Mikolon D, Mielgo A, Stupack DG, Schlaepfer DD.

Oncogene. 2008 Feb 28;27(10):1439-48. Epub 2007 Sep 10.

37.

Cell survival in a three-dimensional matrix.

Alavi A, Stupack DG.

Methods Enzymol. 2007;426:85-101. Review.

PMID:
17697881
38.

Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor.

Nasimuzzaman M, Waris G, Mikolon D, Stupack DG, Siddiqui A.

J Virol. 2007 Oct;81(19):10249-57. Epub 2007 Jul 11.

39.

Does integrin-mediated cell death confer tissue tropism in metastasis?

Lahti JM, Teitz T, Stupack DG.

Cancer Res. 2006 Jun 15;66(12):5981-4. Review.

40.

Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.

Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, Cheresh DA, Schlaepfer DD.

Oncogene. 2006 Sep 28;25(44):5969-84. Epub 2006 May 8.

PMID:
16682956
41.

Halting neuroblastoma metastasis by controlling integrin-mediated death.

Teitz T, Stupack DG, Lahti JM.

Cell Cycle. 2006 Apr;5(7):681-5. Epub 2006 Apr 1.

PMID:
16582638
42.

Potentiation of neuroblastoma metastasis by loss of caspase-8.

Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh DA.

Nature. 2006 Jan 5;439(7072):95-9.

PMID:
16397500
43.

Integrins as a distinct subtype of dependence receptors.

Stupack DG.

Cell Death Differ. 2005 Aug;12(8):1021-30. Review.

44.

Angiogenesis assays in the chick CAM.

Storgard C, Mikolon D, Stupack DG.

Methods Mol Biol. 2005;294:123-36.

PMID:
15576910
45.

Integrins and angiogenesis.

Stupack DG, Cheresh DA.

Curr Top Dev Biol. 2004;64:207-38. Review.

PMID:
15563949
46.

A Bit-role for integrins in apoptosis.

Stupack DG, Cheresh DA.

Nat Cell Biol. 2004 May;6(5):388-9. No abstract available.

PMID:
15122265
47.

Apoptotic cues from the extracellular matrix: regulators of angiogenesis.

Stupack DG, Cheresh DA.

Oncogene. 2003 Dec 8;22(56):9022-9. Review.

PMID:
14663480
48.

Role of Raf in vascular protection from distinct apoptotic stimuli.

Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA.

Science. 2003 Jul 4;301(5629):94-6.

49.

Get a ligand, get a life: integrins, signaling and cell survival.

Stupack DG, Cheresh DA.

J Cell Sci. 2002 Oct 1;115(Pt 19):3729-38. Review.

50.

Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling.

Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D, Cheresh DA.

J Cell Biol. 2002 Apr 1;157(1):149-60. Epub 2002 Apr 1.

Supplemental Content

Loading ...
Support Center